One Month Daily Wear Clinical Evaluation of New Prototype Contact Lenses in Habitual and Neophyte Contact Lens Wearers

NCT ID: NCT02081677

Last Updated: 2018-06-19

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-02-06

Study Completion Date

2014-06-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

There will be four study lenses tested; one marketed lens, and three prototype study lenses. Subjects will be randomized to one of the four study lenses which will be worn in a daily wear modality, with a two week replacement.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Visual Correction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

etafilcon A

Marketed control soft contact lens

Group Type ACTIVE_COMPARATOR

ACUVUE 2

Intervention Type DEVICE

worn in a daily wear modality; lenses will be replaced after 2 weeks

Prototype E1

Investigational soft contact lens

Group Type EXPERIMENTAL

Prototype E1

Intervention Type DEVICE

worn in a daily wear modality; lenses will be replaced after 2 weeks

Prototype E2

Investigational soft contact lens

Group Type EXPERIMENTAL

Prototype E2

Intervention Type DEVICE

worn in a daily wear modality; lenses will be replaced after 2 weeks

Prototype E3

Investigational soft contact lens

Group Type EXPERIMENTAL

Prototype E3

Intervention Type DEVICE

worn in a daily wear modality; lenses will be replaced after 2 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ACUVUE 2

worn in a daily wear modality; lenses will be replaced after 2 weeks

Intervention Type DEVICE

Prototype E1

worn in a daily wear modality; lenses will be replaced after 2 weeks

Intervention Type DEVICE

Prototype E2

worn in a daily wear modality; lenses will be replaced after 2 weeks

Intervention Type DEVICE

Prototype E3

worn in a daily wear modality; lenses will be replaced after 2 weeks

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Investigational soft contact lens Investigational soft contact lens Investigational soft contact lens

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subject must be between 18 and 39 years of age.
2. The subject must be able to read and understand English.
3. The subject read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.
4. The subject must not have been a participant in a contact lens or contact lens solution study/investigation in the previous seven days.
5. The subject must be willing to wearthe study lenses for at least 6 hours per day, 7 days per week (e.g. does not regularly swim).
6. The subject must appear able and willing and able to the adhere to the instructions set forth in this clinical protocol.
7. The subject's subjective refraction must result in a vertex corrected spherical contact lens prescription in the range of -1.00D to -4.00D in each eye.
8. The subject's refractive astigamatism must be less than or equal to -1.00D in both eyes.
9. The subjet must have best corrected visual acuity of 20/30 (6/9 or +0.20 logMAR) or better in each eye.
10. The subject must require a visual correction in both eyes (no monofit or monovision allowed).
11. The subject must have normal eyes with no evidence of abnormality or disease. For the purposes of this study a normal eye is defined as one having:

* No amblyopia
* No evidence of lid abnormality or infection (including blepharitis/meibomitis)
* No conjunctival abnormality or infection.
* No clinically significant slit lamp findings (i.e. stromal edema, vascularization, corneal scaring, infiltrates or abnormal opacities).
* No other active ocular diseases.

Exclusion Criteria

1. Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
2. Any systemic diseases, autoimmune disease, or use of medication, which may interfere with contact lens wear.
3. Clinically significant (Grade 3 or 4) corneal edeam, corneal vascularization, corneal staining, or any other abnormalities of the cornea which would contraindicate contact lens wear.
4. Any ocular infection.
5. Any corneal distortion resulting from previous hard or rigid permeable contact lens wear.
6. Pregnancy or lactation (subjects who become pregnant during the study will be discontinued).
7. No extended wear in the last 3 months.
8. Diabetes.
9. Infectious diseases (e.g. hepatitis, tuberculosis) or immunosuppressive disease (e.g. HIV).
10. Has had refractive surgery.
11. Employee of VRF with direct involvement in the study or a family member of the clinic.
Minimum Eligible Age

18 Years

Maximum Eligible Age

39 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johnson & Johnson Vision Care, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chennai, Tamil Nadu, India

Site Status

Countries

Review the countries where the study has at least one active or historical site.

India

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CR-5146

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.